TCM
VRDN icon

Tang Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Tang Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Hold
1,792,626
– – 1.5% 19
2026
Q1 		$35.1M Hold
1,792,626
– – 1.78% 19
2025
Q4 		$55.8M Sell
1,792,626
-1,050,299
-37% -$28.8M 2.76% 14
2025
Q3 		$61.4M Hold
2,842,925
– – 2.36% 9
2025
Q2 		$39.7M Buy
2,842,925
+50,000
+2% +$679K 2.01% 11
2025
Q1 		$37.6M Buy
2,792,925
+300,000
+12% +$5.11M 2.08% 11
2024
Q4 		$47.8M Buy
2,492,925
+250,000
+11% +$5.44M 3.16% 6
2024
Q3 		$51M Buy
2,242,925
+850,000
+61% +$13.9M 3.65% 4
2024
Q2 		$18.1M Buy
1,392,925
+700,000
+101% +$9.69M 1.85% 14
2024
Q1 		$12.1M Hold
692,925
– – 1.26% 26
2023
Q4 		$15.1M Buy
692,925
+23,800
+4% +$376K 1.39% 21
2023
Q3 		$10.3M Sell
669,125
-23,800
-3% -$454K 1.45% 23
2023
Q2 		$16.5M Hold
692,925
– – 2.43% 13
2023
Q1 		$17.6M Hold
692,925
– – 2.63% 12
2022
Q4 		$20.2M Sell
692,925
-190,000
-22% -$4.38M 2.94% 11
2022
Q3 		$18.1M Buy
882,925
+482,925
+121% +$8.68M 2.22% 14
2022
Q2 		$4.63M Buy
+400,000
New +$5.38M 0.7% 33

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Tang Capital Management's VRDN Position: Q2 2026 in Review

Tang Capital Management held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 1,792,626 shares worth $32.9M. The position accounts for 1.5% of the portfolio, ranked #19.

Tang Capital Management first reported a position in VRDN in Q2 2022 and has held it in 17 quarters since. The position peaked at $61.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Tang Capital Management held 1,792,626 shares of Viridian Therapeutics worth $32.9M as of Q2 2026.
  • Tang Capital Management left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up 1.5% of Tang Capital Management's portfolio in Q2 2026, its #19 holding.
  • Tang Capital Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Tang Capital Management's Viridian Therapeutics position peaked at $61.4M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.